Valuation: Grifols SA

Market Cap 5.91B 6.62B 5.5B 5B 9.45B 641B 9.49B 66.21B 25.94B 327B 24.86B 24.32B 1,048B P/E 2026 *
12.6x
P/E 2027 * 9.62x
Enterprise Value 14.36B 16.08B 13.36B 12.15B 22.94B 1,556B 23.04B 161B 62.99B 793B 60.37B 59.05B 2,546B EV / Sales 2026 *
1.88x
EV / Sales 2027 * 1.72x
Free-Float
79.65%
Yield 2026 *
2.76%
Yield 2027 * 3.05%
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2024
Director of Finance/CFO 49 16/09/2024
Compliance Officer 54 01/01/2014
Director TitleAgeSince
Chairman 76 25/01/2010
Director/Board Member 70 13/04/2000
Director/Board Member 62 24/05/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+3.19%+41.49%+103.56% 1,051B
+1.93%+2.11%+37.08%+65.09% 630B
+1.49%+5.19%+19.94%+85.69% 489B
+2.26%+0.90%+69.32%+40.53% 359B
+1.45%+3.50%+23.29%+41.62% 344B
+1.17%+2.37%+13.47%+33.64% 272B
+0.89%+1.08%-6.13%+9.29% 246B
+1.82%+2.94%+42.99%+52.95% 224B
+2.77%+4.44%+29.01%+98.99% 187B
Average +1.62%+2.53%+30.05%+59.04% 422.63B
Weighted average by Cap. +1.47%+2.44%+33.36%+69.01%

Financials

2026 *2027 *
Net sales 7.65B 8.57B 7.12B 6.48B 12.23B 829B 12.28B 85.7B 33.58B 423B 32.18B 31.48B 1,357B 8.13B 9.11B 7.57B 6.88B 12.99B 881B 13.05B 91.06B 35.68B 449B 34.2B 33.45B 1,442B
Net income 536M 600M 499M 454M 856M 58.08B 860M 6B 2.35B 29.61B 2.25B 2.2B 95.03B 700M 784M 651M 592M 1.12B 75.83B 1.12B 7.84B 3.07B 38.66B 2.94B 2.88B 124B
Net Debt 8.45B 9.46B 7.86B 7.15B 13.49B 915B 13.55B 94.55B 37.05B 467B 35.51B 34.73B 1,497B 8.1B 9.07B 7.54B 6.86B 12.95B 878B 13B 90.73B 35.55B 448B 34.07B 33.33B 1,437B
Logo Grifols SA
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Grifols SA